Portfolio Lab

Acadia Pharmaceuticals Inc

  • Stock
  • Ticker ACAD
  • ISIN US0042251084
  • Nasdaq

Health care · Pharmaceuticals · USA

$17.11 −2.73%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Acadia Pharmaceuticals Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

ACADGlobal equities (VT)

$10,000 grew to $5,976. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −77.2% in 06/2022, measured from the peak in 07/2020. The old peak has not been reached again yet.

1-year return
−25.3%
5-year return p.a.
−2.2%
10-year return p.a.
−5.0%
Volatility p.a.
52.2%
Largest decline
−77.2%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue260244265279284268308342
Gross profit238224244257258243280307
Operating income15419323617-4.63872
EBITDA15420333618-4.33872
Net income1441927722743.63254
Earnings per share0.860.110.160.421.610.020.180.31
Balance sheet
Total assets1,1881,1321,2261,3311,5641,6051,7431,794
Liabilities455367403413337357436407
Equity7337658229171,2271,2481,3071,387
Cash320218254258178282385322
Cash flow
Operating cash flow40206474-493410112
Capital expenditure-0.50.0-0.3-0.4-4.0-5.2-5.1-1.2
Free cash flow40206474-53299610

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2019 at +164.6%, weakest 2021 at −56.3%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
5 Nov 2026$0.31
5 Aug 2026$0.18
7 May 2026$0.02
26 Feb 2026$1.61
6 Nov 2025$0.42
7 Aug 2025$0.16
8 May 2025$0.11
27 Feb 2025$0.86
7 Nov 2024$0.20
7 Aug 2024$0.20
9 May 2024$0.10
28 Feb 2024$0.28

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€2.7bn
Market cap in trading currency
$2.96bn
Enterprise value
$1.98bn
P/E
8.1
P/S
2.46
P/B
2.13
EV/Sales
1.65
EV/EBITDA
16.0
Earnings yield
12.4%
FCF yield
2.8%

Results (last four quarters)

Revenue
$1.20bn
Gross profit
$1.09bn
EBITDA
$124m
Net income
$362m
Earnings per share
$2.12
Revenue per share
$6.96
Revenue growth
+22.8%
Earnings growth
−25.4%

Profitability

Gross margin
90.5%
Operating margin
10.2%
Net margin
30.1%
Return on equity
31.4%
Return on assets
20.2%

Balance sheet and cash flow

Cash
$976m
Cash per share
$5.65
Financial debt
–
Debt/equity %
–
Current ratio
3.82
Book value per share
$8.03
Operating cash flow
$97.5m
Free cash flow
$82.0m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
173m
Volume
1.90m
Avg. volume 3 months
2.19m
Relative volume
0.9

Price and technicals

Price
$17.11
1 day
−2.7%
52-week high
$30.57
52-week low
$16.50
Distance to 52-week high
−44.0%
Distance to 52-week low
+3.7%
Distance to 50-day line
−17.7%
Distance to 200-day line
−26.1%
RSI (14)
34
Volatility 1M
100.3%

Performance

1 week
−8.7%
1 month
−15.8%
3 months
−42.3%
6 months
−18.9%
YTD
−35.9%
1 year
−25.9%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has ACAD performed since 11/2016?

$10,000 grew to $5,976 by 20 Nov 2026, which is −5.0% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ACAD?

Volatility was 52.2% per year, measured on monthly returns. The largest decline from a peak was −77.2%, with the low in 06/2022.

How does ACAD compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, ACAD returned −5.0% at 52.2%. The correlation of monthly returns was 0.25; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Acadia Pharmaceuticals Inc (ACAD): Return and risk